AZ’s Farxiga CKD Trial Hits All Primary, Secondary Targets
DAPA-CKD Was Stopped Early In March For Efficacy
• By Sten Stovall
Study assessed Farxiga’s effect on renal outcomes and CV mortality in chronic kidney disease patients with and without type 2 diabetes. • Source: Shutterstock
Keep up with the top pharma business news of the week. On the go.
